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Abstract Novel insights in the biology of cancer have
switched the paradigm of a “one-size-fits-all” cancer treatment
to an individualized biology-driven treatment approach. In
recent years, a diversity of biomarkers and targeted therapies
has been discovered. Although these examples accentuate the
promise of personalized cancer treatment, for most cancers
and cancer subgroups no biomarkers and effective targeted
therapy are available. The great majority of patients still
receive unselected standard therapies with no use of their
individual molecular characteristics. Better knowledge about
the underlying tumor biology will lead the way toward per-
sonalized cancer treatment. In this review, we summarize the
evidence for a promising cancer biomarker: checkpoint with
forkhead and ring finger domains (CHFR ).CHFR is a mitotic
checkpoint and tumor suppressor gene, which is inactivated in
a diverse group of solid malignancies, mostly by promoter
CpG island methylation. CHFR inactivation has shown to be
an indicator of poor prognosis and sensitivity to taxane-based
chemotherapy. Here we summarize the current knowledge of
altered CHFR expression in cancer, the impact on tumor
biology and implications for personalized cancer treatment.
Keywords CHFR promoter methylation . Predictive
biomarker . Taxane sensitivity
1 Introduction
Over the last 20 years, there has been a revolution in the
perspective of cancer treatment. Improvement of molecular
profiling techniques such as next generation sequencing and
whole genome methylation analysis made it possible to com-
pare thousands of molecules simultaneously with high accu-
racy and speed. These studies have allowed novel and mean-
ingful insights in the biology of cancer. Lung, breast, colorec-
tal and many other cancers have shown to be heterogeneous
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diseases, which develop through specific molecular alterations
that influence the clinical presentation, prognosis and re-
sponse to therapy [1]. The diversity of molecular background
and resultant biological behavior can be harnessed into an
individualized biology-driven treatment, instead of the present
“one-size-fits-all” approach. For some cancers, personalized
cancer treatment is already implemented in daily practice.
In breast cancer treatment, for instance, it is now standard
to test and target increased human epidermal growth factor
receptor 2 (HER2) with both monoclonal antibodies such as
trastuzumab or small molecule inhibitors such as lapatinib [2].
In non-small cell lung cancer (NSCLC) patients, testing for
mutations in EGFR and KRAS , and EML4-anaplastic lym-
phoma kinase (ALK) gene rearrangements to select appropri-
ately targeted therapy occurs on a routine basis. Mutations in
the kinase domain of EGFR have shown to be a strong
predictor of response to EGFR tyrosine kinase inhibitors
(TKIs) erlotinib and gefitinib [3]. These patients respond
better to EGFR TKIs than to chemotherapeutic agents
carboplatin/paclitaxel, reflected by a significantly improved
progression-free survival [4]. Furthermore, patients with
NSCLC harboring the ALK rearrangement, which occurs in
about 7 % of NSCLCs, benefit from ALK inhibitor crizotinib
[5]. A recent prospective randomized phase III study com-
pared crizotinib therapy to chemotherapy, pemetrexed or do-
cetaxel, in 347 locally advanced or metastatic ALK-positive
lung cancers, and clearly showed that crizotinib therapy is
associated with a higher response rate 65 % (95 % CI, 58 to
72) versus 20 % (95 % CI, 14 to 26) (P <0.001) but also an
improved quality of life compared to chemotherapy. The
relatively low incidence of EGFR and ALK aberrations in
non-Asian patients, however, account for the fact that ∼87 %
of patients with NSCLC still receive conventional chemother-
apy with no suitable biomarkers for therapy selection. The
same accounts for women with triple-negative breast cancer
who do not benefit from anti-hormonal therapy or
trastuzumab and for whom effective treatment is limited [6].
Other examples of useful biomarkers are KRAS mutation
testing to predict benefit from monoclonal antibodies against
EGFR, cetuximab and panitumumab, in metastatic colon can-
cer [7] and BRAF V600E mutation analysis in metastatic
melanoma in order to predict responsiveness to BRAF inhib-
itors such as vemurafenib [8]. Salient to this review, testing for
promoter CpG island methylation of DNA repair gene O6-
methylguanine-DNA methyltransferase, MGMT, guides the
clinical management of glioblastoma. MGMT is able to re-
verse the damage acquired by alkylating agents and therefore
promotes methylation, and subsequent silencing ofMGMT is
associated with increased progression-free and overall surviv-
al after therapy with alkylating agents such as temozolomide
[9, 10].
Although these examples display the promise of personal-
ized cancer treatment and more biomarkers are being
discovered, work is still in progress. For most cancers and
cancer subgroups, no biomarkers and effective targeted ther-
apy are available and therefore the great majority of patients
still receive standard therapies with no individualization based
on their tumor’s molecular characteristics.
In this review, we highlight a promising novel biomarker
for which multiple lines of evidence are emerging: checkpoint
with FHA and ring finger domains (CHFR). CHFR is a
mitotic checkpoint- and tumor suppressor gene and is
inactivated in a diverse number of solid malignancies.
CHFR is most frequently inactivated by promoter CpG island
methylation and has shown to be a marker of poor prognosis
and increased sensitivity to treatment with taxanes. Here we
summarize literature on the relevance of altered CHFR ex-
pression in cancer.
2 CHFR: an important regulator of cell cycle progression
CHFR is an early mitotic checkpoint gene that functions as a
key player in controlling chromosomal integrity [11].
CHFR is expressed in the cytoplasm of all normal tissues
and accumulates in the nucleus in response to microtubule
poisoning or radiation damaging stress. After localization into
the nucleus, CHFR becomes phosphorylated by protein kinase
B (PKB/AKT), a member of the PI3K signaling pathway
[12]. The nuclear distribution, mobility and function of
CHFR are dependent upon interaction with promyelocytic
leukemia protein (PML) bodies [13, 14]. CHFR expression
levels fluctuate greatly during different stages of the cell cycle.
Microtubule stress will lead to an elevation of CHFR expres-
sion levels and a mitotic arrest. To the contrary, auto-
ubiquitination activity and degradation of CHFR, which is
stimulated by AKT, are a prerequisite for mitotic entry [15].
Thereby, CHFR controls cell cycle progression at the G2/M
transition as well.
It is not known how CHFR senses microtubule stress, but it
has been shown that CHFR localizes to the mitotic spindle by
an interaction with TCTP, a protein involved in microtubule
stabilization and β-tubulin [16]. Disruption of the spindle
causes CHFR to deliberate from TCTP and the mitotic spin-
dle, which will enable the activation of signaling pathways
and ultimately delay cell cycle progression [17].
These signaling pathways prevent entry into mitosis by
inhibiting the activation of Cdc25 phosphatases that are able
to activate the cyclin B1-Cdk1 kinase.
CHFR is able to influence the mitotic checkpoint by a
proteosomal-dependent and a proteosomal-independent
mechanism (Fig. 1).
CHFR was first described to function as an E3 ubiquitin
ligase, which ubiquitinates and targets proteins for degrada-
tion by the S26 proteosome [15, 18]. One of the target proteins
is polo-like kinase 1 (PLK1). PLK1 is a serine/threonine
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kinase that is involved in the phosphorylation of Cdc25,
thereby regulating cyclin B1-cdk activity. PLK1 phosphory-
lation and activation are established by another kinase, Aurora
A [19–22]. By ubiquitination and degradation of both PLK1
and Aurora A, CHFR is able to inhibit the formation of the
cyclin B1-Cdk complex and thereby promote cell cycle arrest
[20, 23]. Although in vitro data are appealing, evidence that
CHFR targets PLK1 for degradation in vivo as well is weak.
There are conflicting studies that did not observe a decrease in
PLK1 and Aurora A protein expression in response to micro-
tubule poison [24–26]. Differences in study design and mo-
lecular environment make it difficult to compare results and
therefore more studies are needed to clarify this inconsistency.
Other targets for ubiquitination and protein degradation by
CHFR are chromokinesine protein Kif22[27], histone
deacetylase HDAC1[28] and poly(ADP-ribose) 1
PARP1[29]. Kif22 plays a role in the organization of spindle
microtubules and chromosome movement and regulation of
Kif22 activity by CHFR is important for maintaining chromo-
somal stability [27]. HDAC1 is a histone deacetylase that is
able to inhibit the expression of cell cycle genes such as p21.
By ubiquitination of HDAC1, CHFR is able to reverse
HDAC1-induced repression of p21 and thereby restore the
p21-G1 checkpoint [28, 30, 31]. Interestingly, CHFRwas also
shown to inhibit invasiveness and metastatic potential caused
by HDAC1 expression by the regulation of metastasis sup-
pressors, KAI1 and E-cadherin [28].
PARP1 plays a role in the DNA damage response and is
involved in the recruitment of CHFR to DNA damage sites
immediately after DNA damage has occurred [29, 32]. CHFR
then participates in a cascade of protein ubiquitination. One of
the proteins that becomes ubiquitinated and degraded is
PARP-1 itself. Thereby, CHFR is able to detach PARP-1 from
the chromatin, which is an important step in the DNA damage
repair response [29].
CHFR binds to PARP-1 via the RAR-binding zinc finger
domain, which is situated in the cysteine region of CHFR. As
the name illustrates, CHFR contains a N-terminal FHA do-
main, a central RING finger domain, and a C-terminal
cysteine-rich domain (Fig. 2). The function of the FHA do-
main is largely unknown but is required for the checkpoint
function and might be involved in the binding to phosphory-
lated proteins [19]. The RING finger domain is important for
the ubiquitinating activity of CHFR and is able to form lysine
48- and lysine 63-linked polyubiquitination chains [25]. The
cysteine-rich domain is important for the interaction between
CHFR and target proteins [19–22]. Inside the cysteine-rich
region, the RAR-binding zinc-finger (PBZ) is situated which
is able to bind poly(ADP-ribose)PARP family members such
as PARP-1.
Recently, it was shown that CHFR also ubiquitinates and
regulates the expression of TOPK [33]. TOPK is a promitotic
serine/threonine kinase that phosphorylates and inactivates
downstream substrate PTEN, which will lead to activation of
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Fig. 1 CHFR delays entry into metaphase in respons to microtubular stress by effecting target proteins in a proteosome-dependent and a proteosome-
independent manner
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AKT. By inhibiting TOPK, CHFR prevents the TOPK-
induced activation of AKT and thereby blocks G2/M
progression.
CHFR can also influence the mitotic checkpoint by func-
tioning as an ubiquitin ligase that targets proteins not for
degradation but for activation of signal transduction. By cat-
alyzing the formation of noncanonical Lys63-linked
polyubiquitin chains [25], CHFR was shown to activate the
p38 stress kinase pathway, which will reverse chromosome
condensation and induce a mitotic arrest [34].
Furthermore, CHFR indirectly inhibits the nuclear accu-
mulation of cyclin B [24], thereby preventing the for-
mation of the cyclin B1/cdk complex by the same
mechanism, and also interacts with mitotic arrest defi-
cient 2 (MAD2). MAD2 is a key protein in the spindle
assembly checkpoint by its ability to sense improper
spindle attachment and inhibit the anaphase-promoting-
complex [35]. MAD2 is dependent upon binding to
CHFR for its activation and transport to the kineto-
chore. In the absence of CHFR, MAD2 is not able to
inhibit anaphase progression, which will result in mitot-
ic defects [36].
Above-summarized data clearly show that CHFR is an
important regulator of cell cycle progression. Since inactiva-
tion of CHFR promotes chromosomal defects and via activa-
tion of HDAC1 tissue invasion [28], CHFR malfunction is
thought to play an important role in cancer progression and
metastasis.
3 CHFR inactivation in cancer and its role as tumor
suppressor
CHFR is more frequently inactivated in cancer than all other
mitotic checkpoint control genes together [11]. Scolnick et al.
were the first to report lack of CHFR expression in
neuroblastoma and colorectal cancer cell lines [11].
Absence of CHFR in these cell lines resulted in a high
mitotic index when exposed to microtubule stress com-
pared to wild-type cancer cells, which was restored by
reintroduction of functional CHFR. In a breast cancer
cell line model, decreased CHFR expression resulted in an
accelerated growth rate, enhanced invasiveness and amplified
colony formation.
In order to study the physiological role of CHFR and its
function in tumorigenesis, Chfr knockout mice have been
generated [20]. Chfr knockout mice develop invasive lym-
phomas and solid tumors (lung, liver, gastrointestinal) after
40 weeks and have an increased susceptibility to chemical
carcinogenesis [20]. Embryonic fibroblasts from Chfr-defi-
cient mice show substantial aneuploidy and polyploidy.
Therefore, CHFR inactivation is expected to participate in
the acquisition of chromosomal defects and a chromosomal
instability phenotype in cancer. In primary colorectal and
breast cancer tissue, however, CHFR inactivation is not asso-
ciated with chromosomal instability [37]. In colorectal cancer
(CRC) and gastric cancer, CHFR inactivation is associated,
however, with microsatellite instability (MSI) and MLH1
Fig. 2 CHFR gene and protein. Schematic representation of promoter
CpG island methylation, mutation and polymorphisms with functional
significance. of a CHFR gene encompassing 18 exons. CpG island is
enlarged with CpG dinucleotides as vertical lines. TSS: transcription start
site * mutation. # polymorphism. b CHFR protein consisting of 664
aminoacids. FHA: forhead-associated domain. RING: ringfinger domain.
CR: cysteine-rich domain. PBZ: RAR-binding zinc-finger domain. Mu-
tations in black , polymorphism in red
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promoter CpG island methylation. The mechanism un-
derlying the association between CHFR inactivation and
MSI is unknown but might be due to an underlying
DNA methylation defect that causes promoter CpG is-
land methylation of both CHFR and MLH1 . Murine
studies, however, demonstrated that simultaneous loss
of Chfr and Mlh1 synergistically increased predisposi-
tion to cancer development, which implicates a more
functional interaction [38].
Furthermore, a recent study shows an additional role for
CHFR in regulating expression of pro-inflammatory chemo-
kine interleukin-8 (IL-8). CHFR is able to inhibit the NFκB
signaling pathway and IL-8, which subsequently resulted in
decreased angiogenesis and cell migration [39–41].
Inactivation of CHFR triggers NFκB signaling activity and
thereby accelerates angiogenesis and a metastatic phenotype,
which is associated with a poor prognosis.
4 Genetic and epigenetic mechanisms of CHFR
transcriptional silencing
In the last decade, disrupted CHFR expression has been
described in multiple cancer tissues (Table 1). Although
Table 1 CHFR inactivation in multiple cancers
Cancer Aberration Method, region analyzed Percentage of methylation Ref
Breast cancer Reduced expression
Methylation
IHC
demethylation and northern blot
36 % (51/142)
8 % (2/24) (cell lines)
[70]
[71]
Bladder cancer Methylation MLPA 18.7 % (17/91) [72]
Colorectal cancer Methylation COBRA
MSP, −281 to +51 bp
COBRA
MSP, −240 to −73 bp
MSP, −226 to −82 bp
qMSP, +221 to +325 bp
MSP, −240 to −73 bp
40 % (25/63)
37 % (11/30)
53 % (27/51) (adenomas)
41 % (29/71)
26% (25/98)
24 % (217/888)
31 % (19/61)
[73]
[74]
[71]
[75]
[76]
[77]
[67]
Gastric cancer Methylation COBRA
MSP, −9 to +98 bp
COBRA
MSP, −163 to −8 bp
39 % (24/61)
35 % (25/71)
44 % (19/43)
52 % (24/46)
[56]
[78]
[79]
[57]
Nasopharyngeal cancer Methylation MSP, −220 bp to −14 bp
MSP, −220 to −14 bp
61 % (22/36)
59 % (31/53)
[80]
[81]
Non-small cell lung cancer Reduces expression
Methylation
Mutation
IHC
MSP, −220 to −14 bp
MSP, −220 to −14 bp
MSP, −220 to −14 bp/IHC
MSP −195 to −99 bpm
MSP, −220 to −14 bp
MSP, −220 to −14 bp
39 % (16/41)
19 % (7/37)
10 % (2/20)
15 % (3/20)/39 % (69/157)
32.4 % (100/308) (serum)
10 % (16/165)
3.1 % (1/32)
6 % 3/53
[63]
[42]
[74]
[53]
[47]
[52]
[63]
[44]
Esophageal cancer Methylation
Copy number loss
MSP, −163 to −8 bp
MSP, −227 to −86 bp
bisulfite pyrosequencing
qPCR
16.3 % (7/43)
24 % (9/38)
31 % (18/58)
59 % (16/27)
[46]
[82]
[45]
[45]
Cervical cancer Methylation MSP, +168 to 318 12 % (2/14) [59]
Hepatocellular cancer Methylation MSP, −225 to −85 bp 35 % (22/62) [83]
Biliary tract carcinoma Methylation MSP, −9 to +98 bp 16 % (6/37) [84]
Oral squamous cell cancer Methylation MSP, −220 bp −14 bp 31 % (4/13)
34.7 % (17/49)
[85]
[86]
Cutaneous T-cell lymphoma Methylation CpG island microarray 19 % (5/28) [87]
Head and neck cancer COBRA
MS-MLPA
30 % (16/54)
25 % (7/28)
[73]
[88]
Endometrial cancer Methylation MSP, +168 to 318 bp 12 % (6/50) [60]
IHC, immunohistochemistry; (MS)-MLPA, (methylation-specific) multiplex ligation-dependent probe amplification; MSP, methylation-specific PCR;
COBRA, combined bisulfite restriction analysis
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promoter CpG island methylation is the most frequently oc-
curring alteration leading to CHFR inactivation, genetic alter-
ations have been observed occasionally. Scolnick and
Halazonetis were the first to describe a sequence variation in
the cysteine-rich domain of CHFR in osteosarcoma cell
line U2OS [11] (Fig. 2). The variation consisted of a G
to A transition leading to substitution of valine 539 by
methionine and was initially interpreted as a missense
mutation with functional impairment but turned out to
be a polymorphism [42]. The relevance of variant geno-
types was further studied in a series of 462 colorectal cancer
patients and 245 healthy controls [43]. This study showed that
the A allele of the GA variant was associated with a
reduced CRC risk (P =0.02; OR, 0.496; 95 % CI,
0.279–0.883). Thereby, it was shown that polymorphisms
in the CHFR gene can be used as indicator for colorectal
cancer susceptibility.
Additional studies to identify structural variations in the
CHFR coding sequence led to the identification of three
missense mutations in non-small cell lung cancer
(NSCLC); all three were associated with a defective
mitotic checkpoint [44]. Two mutations target the FHA
and RING finger domain and the third is located in the
cysteine-rich region (Fig. 2b). These mutations, howev-
er, were observed in only 3 out of 53 patients. Loss of
the chromosomal region harboring CHFR , 12q24.33, occurs
more frequently. In esophageal adenocarcinomas (EAC),
CHFR DNA copy number loss appears to occur in 59 %
(17/27) of esophageal cancers and is associated with reduced
CHFR expression [45].
In most cancers, however, CHFR expression is reduced
due to promoter CpG island methylation (Fig. 2a). The pro-
moter region of CHFR contains a CpG island spanning −905
to +783 bp relative to the transcription start site. CHFR
promoter CpG island methylation and subsequent transcrip-
tional silencing was first described in esophageal cancer [46],
of which 16.3 % (7/43) was hypermethylated while this was
absent in adjacent normal tissues. Later it became clear that
CHFR promoter CpG island methylation occurs in other
cancers as well, among which CRC (24–53 %) and gastric
cancer (35–52 %) (Table 1). In NSCLC, CHFR promoter
CpG island methylation occurs in approximately 10–40 %
of NSCLCs characterized by wild-type EGFR and KRAS in
absence of ALK gene rearrangement, which implicates that
CHFR promoter CpG island methylation occurs in a specific
NSCLC subgroup [47].
Multiple studies have shown that CHFR promoter
CpG island methylation can be detected not only in
the primary cancers but also in blood (NSCLC) [47],
stool (CRC) [48] and peritoneal fluid (gastric cancer)
[49, 50]. This lends support to CHFR having promise
as a diagnostic marker.
5 CHFR promoter methylation is associated with a poor
prognosis and increased sensitivity to microtubule
inhibitors
5.1 CHFR promoter CpG island methylation as prognostic
marker
In recent years, it has become clear that CHFR promoter CpG
island methylation is associated with a poor prognosis in multi-
ple cancer types. In NSCLC, CHFR promoter CpG island
methylation is associated with an increased risk of disease
recurrence and poor survival [51–53]. In a series of 165
NSCLCs in which the CHFR promoter CpG island was meth-
ylated in 10 % of patients and KRAS and EGFR mutation were
found in 8 % and 29 % of cases, CHFR promoter CpG island
methylation was the only molecular alteration that was associ-
ated with a shorter survival (log-rank test, P=0.0017) [52]. In
colorectal cancer, an association between CHFR promoter CpG
island methylation and poor prognosis has been reported in two
independent studies. Tanake et al. [54] showed in a retrospective
study of 82 resected high-risk stage II or III CRC that CHFR
promoter CpG island methylation (assessed by pyrosequencing)
was associated with a shorter recurrence free survival (log-rank
test, P=0.006) and a reduced overall survival (log-rank test, P=
0.07). We also recently showed that CHFR promoter CpG
island methylation is an indicator of poor survival in stage II
BRAF wild typemicrosatellite stable CRC (n=66,P <0.01, HR
=3.89, 95 % CI=1.58–9.60) and validated these results in an
independent prospective cohort study (n=136, P=0.07, HR=
2.11, 95 % CI=0.95–4.59) (Cleven et al., submitted).
Together, these studies indicate that CHFR promoter CpG
island methylation is an indicator of an aggressive phenotype
characterized by a high risk of disease recurrence and a shorter
overall survival. Testing for CHFR promoter CpG island
methylation may help to select patients with a poor prognosis.
Future studies are needed to investigate which treatment or
screenings approaches will improve survival for patients with
CHFR inactivated cancers.
5.2 CHFR promoter CpG island methylation as predictor
of taxane sensitivity
Although CHFR promoter CpG island methylation is associ-
ated with a poor prognosis, CHFR inactivation predisposes to
an increased sensitivity to microtubule inhibitors (Table 2).
Microtubule inhibitors such as docetaxel and paclitaxel dis-
rupt normal microtubule dynamics during cell division by
binding to the beta-tubulin subunits. This will lead to a failure
of microtubule separation and apoptosis. As CHFR is
able to block entry into prophase until chromosomal
alignment is restored, CHFR inhibits the effect of
taxanes. Accordingly, cells expressing CHFR are more
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viable upon treatment with microtubule inhibitors com-
pared to cells not expressing CHFR [55].
The association between CHFR expression and decreased
sensitivity to microtubule inhibitors was first shown by Satoh
et al. in gastric cancer cell lines [56]. Docetaxel or paclitaxel is
a standard treatment option for gastric cancer, though not all
patients will respond to this therapy. CHFR promoter CpG
island methylation was hypothesized to be an important de-
terminant of response to therapy. In a small study of 12
patients with advanced stage gastric cancer that received
adjuvant paclitaxel, CHFR promoter CpG island methylation
was associated with a better clinical response compared to
cancers with unmethylated CHFR of which the majority
showed progressive disease [57]. These results could, howev-
er, not be confirmed in a larger study of 41 gastric cancers in
which promoter CpG island methylation was not associated
with response to docetaxel or paclitaxel [58]. Of note, clinical
response, however, was measured in metastatic lesions where
the methylation status of CHFR was not assessed.
Stronger support for the potential role for CHFR promoter
CpG island methylation in predicting response to microtubule
inhibitors has been described in other cancer types. Cervical
adenocarcinoma cell lines (n =6) with CHFR promoter CpG
islandmethylation, for instance, are sensitive to treatment with
docetaxel and paclitaxel [59]. Treatment with 5-Aza-2′-
deoxycytidine recovered CHFR expression and de-
creased the sensitivity to these agents immediately, an
effect that was not observed for treatment with 5-
fluorouracil, etoposide, cisplatin and doxorubicin. The
same accounts for CHFR promoter CpG island
methylation and treatment with paclitaxel in endometrial
cancer cell lines [60, 61] and in NSCLCs [62].
Other preclinical evidence for CHFR as marker of taxane
sensitivity comes from a recent retrospective study that ana-
lyzed CHFR inactivation and response to paclitaxel in meta-
static NSCLC [63]. CHFR promoter CpG island methylation
was assessed with MSP and validated by methylation micro-
array and nuclear expression of CHFR was analyzed by
immunohistochemistry. Although CHFR promoter CpG is-
land methylation was observed in only 1/32 (3.1 %) patients,
16/41 (37 %) patients showed reduced nuclear staining of
CHFR , indicating the presence of a CHFR repressive event
other than promoter CpG island methylation that still needs to
be elucidated. In this study diminished nuclear CHFR expres-
sion was associated with a better response to therapy (19 %
versus 52 % progression at first restaging, P=0.033) and a
prolonged overall survival (9.1 versus 5.1 months, HR 0.28,
95 % CI=0.14–0.56) compared to patients with high CHFR
nuclear expression.
Finally, in colorectal cancer, a recently reported preclinical
study showed increased sensitivity to taxanes in colorectal
cancer cell lines both in vitro and in vivo . The correlation
between CHFR expression and resistance to docetaxel was
statistically significant (P=0.033), with a 20-fold increase in
median IC50 for cell lines that had measurable CHFR expres-
sion versus silenced cell lines [64].
Although randomized prospective clinical trials are needed
before implementation into clinical practice, these studies
together strongly support the evidence for CHFR inactivation
as marker of taxane sensitivity.
Table 2 CHFR inactivation as prognostic and predictive marker
Cancer prognostic marker Method Ref
Lung cancer Reduced CHFR expression associated with poor prognosis (n =157)
CHFR Promoter methylation associated with poor prognosis (n=208)
IHC
MSP
[53]
[51]
Colorectal cancer CHFR promoter methylation associated with poor prognosis in stage II MSS BRAF wt CRC
(n=66).
Confirmed in second independent series (n =136)
CHFR promoter methylation associated with reduced recurrence-free and overall survival
(n=82)
MSP
PS
[54]
Predictive marker
Gastric cancer CHFR promoter methylation associated with increased sensitivity to paclitaxel (cell lines n =4)
CHFR promoter methylation associated with increased sensitivity to paclitaxel (n =12)
No relationship between CHFR promoter methylation and sensitivity to docetaxel or paclitaxel
(n=41)
MSP
MSP
COBRA
[56]
[57]
[58]
Cervical cancer CHFR promoter methylation associated with increased sensitivity to paclitaxel (cell lines, n =6) MSP [59]
Oral squamous cell carcinomas Silencing of CHFR with siRNA increases taxane sensitivity (cell lines) siRNA [85]
Lung cancer CHFR promoter methylation associated with increased sensitivity to paclitaxel (n =69 and 41)
Unmethylated CHFR promoter associated with good response to EGFR TKIs (n =179)
Reduced CHFR expression predicts outcome to paclitaxel based therapy (n =41)
MSP
MSP
IHC
[62, 63]
[47]
[63]
Endometrial cancer CHFR promoter methylation associated with increased sensitivity to paclitaxel (cell lines, n =6) MSP [60, 61]
IHC, immunohistochemistry; MSP, methylation-specific PCR; PS, pyrosequencing; siRNA short interference RNA; TKI, tyrosine kinase inhibitors
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6 Conclusion
In the last decade, a substantial number of studies have been
performed to investigate CHFR inactivation, usually due to
promoter CpG island methylation, as biomarker to predict
prognosis and response to microtubule inhibitors in a diversity
of cancers. There is compelling evidence that reduced CHFR
expression is a promising biomarker that can improve the
management of multiple tumor types.
The clinical impact of CHFR promoter CpG island meth-
ylation as prognostic marker will be in the selection of patients
with an aggressive phenotype. In stage II CRC, CHFR pro-
moter CpG island methylation can help to identify patients
with a worse prognosis that might benefit from adjuvant
therapy. The same accounts for CHFR inactivation as
predictive marker of taxane sensitivity where CHFR
inactivation can help to select patients for taxane treat-
ment. Furthermore, these results can be a rationale for
studying the effect of taxane treatment in cancers with
CHFR inactivation. A prospective trial to test this hypothesis
in CRC is presently ongoing.
The clinical value of any biomarker, however, depends on
the accuracy of the test. The majority of candidate biomarkers
reported in literature do not reach clinical use mostly because
they fail to pass the validation phase. This can be explained by
intra- and inter-tumor heterogeneity, a technical inability to
consistently verify the presence of the biomarker in patient’s
material, and the lack of specificity for a particular disease. In
most studies, CHFR promoter CpG island methylation is
assessed by methylation-specific PCR (MSP). MSP is a very
sensitive qualitative method that is able to detect aberrant
methylation in minute amounts of DNA [65]. One important
aspect of the technique is the region selected to be analyzed
since not all regions within the CpG island have biological and
clinical relevance [66]. In the literature, however, different
locations within the promoter CpG island ofCHFR have been
analyzed (Table 1), which makes it difficult to compare re-
sults. CpG methylation within region −240 to −73 bp relative
to the transcription start site of CHFR has shown to result in
gene silencing [46] and is therefore proposed as core region of
promoter methylation [67].
One of the technical challenges of MSP is a false positive
result due to inadequacy of bisulfite treatment and mispriming
especially when nested PCR or high numbers of PCR cycles
are used [65]. Several alternative methods are available among
which pyrosequencing [68]. Pyrosequencing permits a quan-
titative methylation analysis with single nucleotide resolution
of the amplified region but also relies on amplification of
bisulfite-converted DNA. One of the challenges of pyrose-
quencing, however, is that the technique requires a numeric
cutoff value to define a positive methylation status, which is
difficult in a clinical setting that is dependent upon biopsy
specimens that are usually small and do not allow correction
for tumor heterogeneity or involvement of normal tissues. The
same accounts for other quantitative (q)MSP techniques.
Besides MSP, pyrosequencing and qMSP, recently also
ultra-deep next-generation-based bisulfite sequencing has be-
come available. Future studies are needed to evaluate the
performance of the different techniques in assessing CHFR
methylation status in a clinical setting. Since all associations
between CHFR promoter methylation and clinical variables
(Table 2) until now are consistently found with MSP, at
present MSP is the more promising method of choice.
Furthermore, large, independent cohort studies and clinical
trials are needed to validate the prognostic and predictive
value of CHFR inactivation. These trials will need to be
compared to established clinical markers such as Tumor-
Node-Metastasis (TNM) classification system. Simon et al.
have proposed a less time consuming design in which archival
material of prospective trials is used to investigate the perfor-
mance of a single biomarker [69].
In conclusion, the combination of the crucial role ofCHFR
in mitotic checkpoint control and a clear prognostic and
predictive power highlights the clinical potential of CHFR
as biomarker. Although work is still in progress, currently
available results all point into the same direction and make
CHFR inactivation, mostly due to promoter CpG island meth-
ylation, a biomarker with great potential and the development
of clinical trials to validate its predictive and prognostic value,
a priority.
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